In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Non-ST-Segment Elevation Myocardial Infarction (NSTEMI) Registry



Introduction

stethoscope heartNon-ST-segment elevation myocardial infarction (NSTEMI) is a global health and economic burden.

We are launching a EURObservational Research Programme (EORP) NSTEMI Registry, which aims to improve the clinical outcomes of patients hospitalised with NSTEMI, through the identification and reporting of sub-optimal delivery of guideline-indicated care.

Non-ST-segment elevation myocardial infarction (NSTEMI) is a global health and economic burden. NSTEMI is a leading cause of emergency hospitalisation across Europe and USA and, for example, accounts for over 50,000 admissions to hospital each year in the National Health Service of England and Wales 1-3.

Clinical outcomes from NSTEMI may be improved through the use of guideline-indicated treatments including evidence-based pharmacological therapies and invasive coronary procedures 4, 5. A number of cohort studies have shown that improving adherence to evidence-based interventions reduces the risk of death after NSTEMI 5-7. However, between and within European country variation in the delivery and outcomes from NSTEMI suggest that the potential to reduce the burden of cardiovascular disease has not been realised 2, 5, 6.

Recently, the European Society of Cardiology (ESC) reported the results of two programmes of work which are central to the management and quality improvement of patients with NSTEMI. The first document, the 2015 ESC guideline for the management of acute coronary syndromes in patients without persistent ST-segment elevation, sets out the evidence-based road map for the optimal care of patients with NSTEMI 4. The second document, entitled Quality indicators for acute myocardial infarction: A position paper of the Acute Cardiovascular Care Association, details across seven domains and 20 indicators specific quality assessment indicators that include evidence–based process measures mapped to the 2015 NSTEMI guidelines and non-evidence-based dimensions important for quality improvement 8.

External validation studies in the United Kingdom (UK) and France suggest that the majority of the Quality Indicators (Qis) were significantly inversely associated with 30-day and –year mortality 9, 10 – that is, greater attainment of the ESC standards of NSTEMI care is associated with better clinical outcomes.

Objectives

The aim of the EURObservational Research Programme (EORP) NSTEMI registry is to improve the clinical outcomes of patients hospitalised with NSTEMI, through the identification and reporting of sub-optimal delivery of guideline-indicated care.

The registry will aim to quantify the gaps in the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation versus the current guidelines, and describe the inter-country differences.

This registry will also allow analysis and reporting of these data, in the form of research publications and health reports, to the wider ESC community.

Characteristics

Patients presenting with NSTEMI will be eligible. There is no limitation in terms of number of patients or sites.

Participating sites will have to include patients and enter the data in an online CRF. The registry will be a snapshot over a period of two weeks. During this period all patients presenting with NSTEMI will be asked to enter the registry (baseline data and survival follow-up at 30 days). The two-week period will be chosen at the discretion of the site.

If you are interested in participating, please contact eorp@escardio.org.

The NSTEMI Registry Executive Committee

 ludman-peter-2014.jpg

 

 

Peter Ludman, Co-Chair

 

Christopher Peter Gale (UK)
Andrzej Budaj (PL)
Hector Bueno (ES)
Kurt Huber (AT)
Maddalena Lettino (IT)
Sergio Leonardi (IT)
Dejan Milasinovic (RS)
Salvatore Brugaletta (ES)
Vijay Kunadian (UK)
Yolande Appelman (NL)
Aldo P. Maggioni (IT)